RT Journal Article
T1 Clinical Characteristics, Treatment Persistence, and Outcomes Among Patients With COPD Treated With Single- or Multiple-Inhaler Triple Therapy: A Retrospective Analysis in Spain.
A1 Alcázar-Navarrete, Bernardino
A1 Jamart, Lucía
A1 Sánchez-Covisa, Joaquín
A1 Juárez, Mónica
A1 Graefenhain, Ruth
A1 Sicras-Mainar, Antoni
K1 COPD
K1 fixed-dose combinations
K1 inhaled corticosteroids (ICS)
K1 long-acting muscarinic antagonists (LAMA)
K1 long-acting β2-agonists (LABA)
K1 multiple-inhaler triple therapy (MITT)
K1 persistence
K1 single-inhaler triple therapy (SITT)
AB COPD is a leading cause of death and disability. COPD therapy goals include reducing exacerbations and improving symptom control. Single-inhaler triple therapy (SITT) or multiple-inhaler triple therapy (MITT) is indicated for patients with frequent exacerbations despite bronchodilator therapy. No available evidence compares SITT vs MITT in Spain in terms of treatment persistence, exacerbations, and other outcomes. Do COPD patients in Spain initiating SITT vs MITT have improved persistence, exacerbations, and health care resource utilization? This real-world, observational, retrospective cohort study analyzed electronic health records in the Spanish National Healthcare System BIG-PAC database to identify COPD patients aged ≥ 40 years initiating SITT or MITT (using two or three inhalers) between June 1, 2018 and December 31, 2019. Comparative data on persistence (allowing up to 60 days without prescription refill), exacerbation rates, and health care resource utilization and costs during 12-month follow-up were analyzed. Multivariate adjusted analyses were performed. Eligible patients (N = 4,625) initiating SITT (n = 1,011) or MITT (n = 3,614) had a mean age of 70.9 years; most were male (73.9%) with mainly moderate (62.0%) or severe (26.5%) airflow limitation. Between-cohort baseline characteristics were similar. At 12-month follow-up, SITT patients had higher persistence (hazard ratio [HR] = 1.37; 95% CI = 1.22-1.53; P  Patients initiating SITT had a clinically relevant improvement in persistence leading to reductions in mortality, incidence of exacerbations, and health care resource use with consequent mean cost savings.
YR 2022
FD 2022-07-03
LK http://hdl.handle.net/10668/22088
UL http://hdl.handle.net/10668/22088
LA en
DS RISalud
RD Apr 8, 2025